UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
In a report released today, Matthew Weston from UBS maintained a Hold rating on GlaxoSmithKline, with a price target of £19.40.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Weston is a 4-star analyst with an average return of 10.3% and a 72.48% success rate.
In addition to UBS, GlaxoSmithKline also received a Hold from Bank of America Securities’s Sachin Jain in a report issued on June 9. However, on the same day, Barclays maintained a Sell rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p7.63 billion and a net profit of p1.74 billion. In comparison, last year the company earned a revenue of p7.52 billion and had a net profit of p1.62 billion
Based on the recent corporate insider activity of 327 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK announces momelotinib granted ODD from U.S. FDA, EMA
- GSK’s momelotinib wins US and EU orphan status for rare VEXAS syndrome
- GSK Executives Acquire Shares Under Company Reward Plan
- GSK US President Acquires Notional ADS Under Executive Savings Plan
- Nike downgraded, Oscar Health upgraded: Wall Street’s top analyst calls
